Biogen ALS Drug Showed No Benefit, O'Neill Says

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change